I am not overwhelmed but am encouraged by the news. Seeing stronger effects in patients treated in second period (placebo then DMX-200) vs vice-versa is consistent with a legacy effects in this crossover design (I.e the good effects of DMX-200 taking longer than expected to wash out). The risk-reward profile here, especially given potential REMAP-CAP upside with continued GWAS hits near CCR2, continues to look favorable to me. Of course I would have welcomed partnership news but this is a decent step.
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-4
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $186.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.0¢ | 33.0¢ | $384.6K | 1.155M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 313872 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 126595 | 4 |
View Market Depth
| Last trade - 14.38pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
33.5¢ |
Change
-0.005 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 34.0¢ | 33.0¢ | 561183 | ||
| Last updated 14.51pm 24/05/2024 ? | |||||
| DXB (ASX) Chart |